Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Novartis AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Introduction: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Clinical Trials

Switching to Iloperidone From Other Antipsychotics in Schizophrenia

Phase 4

Completed

Conditions: Schizophrenia

Interventions: Drug: iloperidone

First Posted Date: 2010-09-22

Last Posted Date: 2013-03-15

Lead Sponsor: Novartis

Target Recruit Count: 501

Registration Number: NCT01207414

Locations: 🇺🇸
Birmingham Psychiatry Pharmaceutical Studies, Inc., Birmingham, Alabama, United States
🇺🇸
Comprehensive Neuroscience, Fresh Meadows, New York, United States
🇺🇸
ATP Clinical Research Center, Inc., Costa Mesa, California, United States

and more 53 locations

Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Fingolimod
Biological: Seasonal influenza vaccine
Biological: Tetanus toxoid vaccine

First Posted Date: 2010-09-13

Last Posted Date: 2012-06-19

Lead Sponsor: Novartis

Target Recruit Count: 138

Registration Number: NCT01199861

Locations: 🇬🇧
Novartis Investigative Site, Stoke-on-Trent, United Kingdom
🇨🇭
Novartis Investigational Site, Basel, Switzerland

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: vildagliptin/metformin

First Posted Date: 2010-09-08

Last Posted Date: 2017-08-01

Lead Sponsor: Novartis

Target Recruit Count: 161

Registration Number: NCT01196546

Locations: 🇹🇭
BMA Medical College and Vajira Hospital, Bangkok, Thailand
🇹🇭
King Chulalongkorn Memorial Hospital, Bangkok, Thailand
🇹🇭
Phamongkutklao Hospital, Bangkok, Thailand

and more 5 locations

Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)

Phase 2

Completed

Conditions: Typhoid Fever

Interventions: Biological: NVGH Vi-CRM197 12.5 mcg
Biological: NVGH Vi-CRM197 5.0 mcg
Biological: NVGH Vi-CRM197 1.25 mcg
Biological: Vi-polysaccharide vaccine

First Posted Date: 2010-09-02

Last Posted Date: 2014-01-17

Lead Sponsor: Novartis

Target Recruit Count: 88

Registration Number: NCT01193907

Locations: 🇧🇪
Center for the Evaluation of Vaccination (CEV), Antwerp, Wilrijk (Antwerp), Belgium

Glycemic Holter Study (Continuous Glucose Monitoring) -

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Vildagliptin
Drug: Sitagliptin

First Posted Date: 2010-09-01

Last Posted Date: 2012-05-04

Lead Sponsor: Novartis

Target Recruit Count: 36

Registration Number: NCT01193296

Locations: 🇫🇷
Investigative Site, Venissieux, France

Certoparin in Renal Patients Undergoing Hemodialysis

Phase 3

Completed

Conditions: Renal Dialysis

Interventions: Drug: Certoparin

First Posted Date: 2010-08-11

Last Posted Date: 2012-07-10

Lead Sponsor: Novartis

Target Recruit Count: 109

Registration Number: NCT01179620

Locations: 🇩🇪
Novartis Investigative Site Darmstadt, Darmstadt,, Germany
🇩🇪
Novartis Investigative Site Elsenfeld, Elsenfeld, Germany
🇩🇪
Novartis Investigative Site Flensburg, Flensburg, Germany

and more 6 locations

Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Valsartan/Amlodipine
Drug: Nifedipine

First Posted Date: 2010-07-22

Last Posted Date: 2012-06-01

Lead Sponsor: Novartis

Target Recruit Count: 564

Registration Number: NCT01167153

Locations: 🇨🇳
Novartis Pharmaceuticals, Beijing, China

Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures

Phase 2

Withdrawn

Conditions: Partial Onset Seizures

Interventions: Drug: BGG492
Drug: Placebo

First Posted Date: 2010-07-22

Last Posted Date: 2012-05-01

Lead Sponsor: Novartis

Registration Number: NCT01167335

Locations: 🇺🇸
University of South Alabama, Mobile, Alabama, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸
Epilepsy Care Specialists, S.C., Milwaukee, Wisconsin, United States

and more 2 locations

Zoledronic Acid in MS-patients With Osteoporosis

Phase 3

Terminated

Conditions: Osteoporosis
Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Zoledronic Acid
Dietary Supplement: Calcium and Vitamin D combination

First Posted Date: 2010-07-20

Last Posted Date: 2013-11-26

Lead Sponsor: Novartis

Target Recruit Count: 29

Registration Number: NCT01166178

Locations: 🇩🇪
Novartis Investigative Site, Siegen, Germany
🇩🇪
Novartis investigative site, Stade, Germany

Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

Completed

Conditions: Cancer

Interventions: Drug: Treatment

First Posted Date: 2010-07-12

Last Posted Date: 2016-03-28

Lead Sponsor: Novartis

Target Recruit Count: 288

Registration Number: NCT01160094

Locations: 🇸🇦
Novartis Investigative Site, Riyadh, Saudi Arabia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy